Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Radiotherapy and Immunotherapy in Advanced RCC
NCT06255223Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- Dec 2023
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in renal cell carcinoma (RCC), sponsored by Jinling Hospital. Primary endpoints: Disease Control Rate at 1 year and Incidence of Adverse Events at 1 year. Started Dec 2023; status: recruiting.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06255223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255223.